Insider10% Owner
TANG KEVIN Insider Trading Activity
Every SEC Form 4 transaction reported by TANG KEVIN, sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Is TANG KEVIN buying or selling?
TANG KEVIN reported 63 open-market buys ($222.2M) and 7 sells ($120.9M) across 70 Form 4 filings at 11 companies — a net buying position of $101.2M.
Source: SEC EDGAR Form 4
Key Statistics (as of Aug 28, 2026)
Total Form 4 filings
70
SEC EDGAR
Companies
11
Buys (63)
$222.2M
Sells (7)
$120.9M
Insider sentiment
Net buyingNet insider flow of $101.2M in net buying, filed between Feb 16, 2018 – Aug 28, 2026.
Companies TANG KEVIN files for
| # | Company | Form 4 filings |
|---|---|---|
| 1 | ODTOdonate Therapeutics, Inc. | 29 |
| 2 | LJPCLA JOLLA PHARMACEUTICAL CO | 12 |
| 3 | BOLDBoundless Bio, Inc. | 7 |
| 4 | AUPHAurinia Pharmaceuticals Inc. | 5 |
| 5 | TCRRTCR2 THERAPEUTICS INC. | 4 |
| 6 | APVOAptevo Therapeutics Inc. | 3 |
| 7 | HRTXHERON THERAPEUTICS, INC. /DE/ | 3 |
| 8 | RAINRain Oncology Inc. | 3 |
| 9 | FULCFulcrum Therapeutics, Inc. | 2 |
| 10 | JNCEJounce Therapeutics, Inc. | 1 |
Recent TANG KEVIN transactions
| Date | Ticker | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 28, 2026 | BOLD | 10% Owner | Sale | 18.3K | $54.4K |
| Jul 21, 2026 | BOLD | 10% Owner | Purchase | 4.9K | $11.9K |
| Jul 21, 2026 | FULC | 10% Owner | Purchase | 167.6K | $594.7K |
| Jul 17, 2026 | BOLD | 10% Owner | Purchase | 64.0K | $155.6K |
| Jul 15, 2026 | FULC | 10% Owner | Purchase | 249.9K | $891.1K |
| Jul 13, 2026 | BOLD | 10% Owner | Purchase | 91.6K | $222.1K |
| Jul 9, 2026 | BOLD | 10% Owner | Purchase | 57.2K | $141.9K |
| Jul 2, 2026 | BOLD | 10% Owner | Purchase | 107.5K | $268.9K |
| Jun 29, 2026 | BOLD | 10% Owner | Purchase | 286.3K | $714.8K |
| Jun 3, 2026 | AUPH | Chief Executive Officer | Purchase | 814.6K | $12.5M |
| Mar 3, 2026 | AUPH | Director | Purchase | 900.0K | $12.7M |
| Aug 5, 2025 | AUPH | Director | Purchase | 1.3M | $13.6M |
| Mar 4, 2025 | AUPH | Director | Purchase | 1.6M | $12.7M |
| Dec 9, 2024 | AUPH | Director | Purchase | 1.2M | $10.8M |
| Sep 18, 2024 | OMIC | 10% Owner | Purchase | 122.4K | $1.8M |
| Dec 18, 2023 | RAIN | 10% Owner | Sale | 174.0K | $209.4K |
| Oct 13, 2023 | RAIN | 10% Owner | Purchase | 284.1K | $279.0K |
| Jun 1, 2023 | RAIN | 10% Owner | Purchase | 1.1M | $1.2M |
| May 31, 2023 | TCRR | 10% Owner | Purchase | 50.0K | $86.0K |
| May 15, 2023 | TCRR | 10% Owner | Purchase | 44.9K | $87.6K |
| May 10, 2023 | TCRR | 10% Owner | Purchase | 84.0K | $163.8K |
| May 5, 2023 | TCRR | 10% Owner | Purchase | 289.6K | $547.9K |
| Mar 15, 2023 | JNCE | 10% Owner | Purchase | 86.0K | $86.0K |
| Dec 2, 2021 | LJPC | Director, 10% Owner | Sale | 441.3K | $1.7M |
| Nov 26, 2021 | APVO | Other | Sale | 921.3K | $10.4M |
Showing the 25 most recent filings of 70. Screen every filing.
TANG KEVIN insider trading FAQ
Is TANG KEVIN buying or selling?
Across 70 SEC Form 4 filings, TANG KEVIN reported 63 open-market purchases totaling $222.2M and 7 sales totaling $120.9M — a net buying position of $101.2M.
Which companies does TANG KEVIN file Form 4s for?
TANG KEVIN has reported insider transactions at 11 companies, most often Odonate Therapeutics, Inc. (ODT), LA JOLLA PHARMACEUTICAL CO (LJPC), Boundless Bio, Inc. (BOLD), Aurinia Pharmaceuticals Inc. (AUPH), TCR2 THERAPEUTICS INC. (TCRR).
How far back does TANG KEVIN's filing history go?
Trabud holds TANG KEVIN's SEC Form 4 filings from Feb 16, 2018 – Aug 28, 2026, sourced directly from SEC EDGAR.
Where does Trabud get TANG KEVIN's insider trading data?
Directly from SEC EDGAR Form 4 filings. Every transaction on this page is a real filing accepted by the SEC, updated as new filings arrive.
Related Content
Track TANG KEVIN and every other insider
Screen all SEC Form 4 filings by insider, company, transaction value, and role — or ask Trabud's AI agent in plain English.
Open the screener